Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Already have an account: Login
Genetic Engineering Publications - GEG Tech top picks
36.6K views |
+0 today
 Your new post is loading...
Your new post is loading...
|
Although the MAPK pathway drives proliferation in RAS- or RAF-mutant cancers, small-molecule
RAF and MEK inhibitors have had limited success in treating RAS- or RAF-mutant cancers.
Using genome-scale CRISPR-Cas9 resistance screens, Wang et al. identify the AXN1L-CIC-ETS
transcription factor axis as a mediator of resistance to MAPK pathway inhibition.